Florica Therapeutics develops exosome-based therapeutics that deliver targeted molecular therapies to enhance cellular function and resilience against aging. Their approach aims to extend lifespan and prevent age-related diseases by utilizing exosomes for precise therapeutic delivery.
Funding
$275.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
A significant challenge in treating neurological diseases is the blood-brain barrier, which restricts the delivery of drugs to the brain, leading to frequent failures in clinical trials. Current methods lack effective ways to transport biologics and gene therapies across this barrier.
Solution
Florica Therapeutics is developing a novel brain cell-derived component, created in vitro, designed to encapsulate drugs, specifically biologics and gene therapy products, to facilitate their delivery across the blood-brain barrier. This technology aims to enable the treatment of numerous neurological diseases by improving drug delivery to the brain. Their initial focus is on gene therapy drugs for rare pediatric neurological diseases, with a specific emphasis on Tay-Sachs Disease.
Target Audience
The primary target audience includes patients with neurological diseases, particularly those with rare pediatric neurological conditions like Tay-Sachs Disease, and the clinicians treating these conditions.
Features
- Novel brain cell component for drug encapsulation
- Designed for delivery of biologics and gene therapy products across the blood-brain barrier
- In-vitro creation of the drug delivery component
- Focus on gene therapy for rare pediatric neurological diseases
- Initial indication: Tay-Sachs Disease